Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
Beteiligte:
Raetz, Elizabeth A.;
Bhatla, Teena
Erschienen:
American Society of Hematology, 2012
Erschienen in:
Hematology, 2012 (2012) 1, Seite 129-136
Sprache:
Englisch
DOI:
10.1182/asheducation.v2012.1.129.3800156
ISSN:
1520-4383;
1520-4391
Entstehung:
Anmerkungen:
Beschreibung:
Abstract Acute lymphoblastic leukemia (ALL) is the most common and one of the most treatable cancers in children. Although the majority of children with ALL are now cured, 10%-20% of patients are predicted to relapse and outcomes with salvage therapy have been disappointing, with approximately only one-third of children surviving long-term after disease recurrence. Several prognostic factors have been identified, with timing of recurrence relative to diagnosis and site of relapse emerging as the most important variables. Despite heterogeneity in the elements of salvage therapy that are delivered in trials conducted internationally, outcomes have been remarkably similar and have remained static. Because most intensive salvage regimens have reached the limit of tolerability, current strategies are focusing on identifying new agents tailored to the unique biology of relapsed disease and identifying methods to develop these agents efficiently for clinical use. Recently, high-resolution genomic analyses of matched pairs of diagnostic and relapse bone marrow samples are emerging as a promising tool for identifying pathways that impart chemoresistance.